Cespi et al., 2014 - Google Patents
Use of in-die powder densification parameters in the implementation of process analytical technologies for tablet production on industrial scaleCespi et al., 2014
View PDF- Document ID
- 12607742502546993953
- Author
- Cespi M
- Perinelli D
- Casettari L
- Bonacucina G
- Caporicci G
- Rendina F
- Palmieri G
- Publication year
- Publication venue
- International Journal of Pharmaceutics
External Links
Snippet
The use of process analytical technologies (PAT) to ensure final product quality is by now a well established practice in pharmaceutical industry. To date, most of the efforts in this field have focused on development of analytical methods using spectroscopic techniques (ie …
- 238000000034 method 0 title abstract description 41
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/15—Medicinal preparations; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Karande et al. | In-line quantification of micronized drug and excipients in tablets by near infrared (NIR) spectroscopy: Real time monitoring of tabletting process | |
Hausman et al. | Application of Raman spectroscopy for on-line monitoring of low dose blend uniformity | |
Hou et al. | Quantifying effects of particulate properties on powder flow properties using a ring shear tester | |
Franch-Lage et al. | Fast assessment of the surface distribution of API and excipients in tablets using NIR-hyperspectral imaging | |
Porfire et al. | High-throughput NIR-chemometric methods for determination of drug content and pharmaceutical properties of indapamide powder blends for tabletting | |
Peinado et al. | Development, validation and transfer of a near infrared method to determine in-line the end point of a fluidised drying process for commercial production batches of an approved oral solid dose pharmaceutical product | |
Bakri et al. | Assessment of powder blend uniformity: Comparison of real-time NIR blend monitoring with stratified sampling in combination with HPLC and at-line NIR Chemical Imaging | |
Razuc et al. | Near-infrared spectroscopic applications in pharmaceutical particle technology | |
Lee et al. | Quality by Design (QbD) approach to optimize the formulation of a bilayer combination tablet (Telmiduo®) manufactured via high shear wet granulation | |
Pestieau et al. | Towards a real time release approach for manufacturing tablets using NIR spectroscopy | |
Souihi et al. | Design space estimation of the roller compaction process | |
McAuliffe et al. | The use of PAT and off-line methods for monitoring of roller compacted ribbon and granule properties with a view to continuous processing | |
Blanco et al. | Controlling individual steps in the production process of paracetamol tablets by use of NIR spectroscopy | |
Nesarikar et al. | Instrumented roll technology for the design space development of roller compaction process | |
Kandpal et al. | Quality assessment of pharmaceutical tablet samples using Fourier transform near infrared spectroscopy and multivariate analysis | |
Mohan et al. | A robust quantitative near infrared modeling approach for blend monitoring | |
da Costa et al. | Measurement of the amorphous fraction of olanzapine incorporated in a co-amorphous formulation | |
Nakagawa et al. | Real-time monitoring of lubrication properties of magnesium stearate using NIR spectrometer and thermal effusivity sensor | |
Sun et al. | Ribbon density and milling parameters that determine fines fraction in a dry granulation | |
Gentis et al. | Compressibility of binary powder formulations: Investigation and evaluation with compaction equations | |
Zhao et al. | A new parameter for characterization of tablet friability based on a systematical study of five excipients | |
Gamble et al. | Monitoring process induced attrition of drug substance particles within formulated blends | |
Juban et al. | Processing-induced-transformations (PITs) during direct compression: Impact of tablet composition and compression load on phase transition of caffeine | |
Cespi et al. | Use of in-die powder densification parameters in the implementation of process analytical technologies for tablet production on industrial scale | |
Boersen et al. | The influence of API concentration on the roller compaction process: modeling and prediction of the post compacted ribbon, granule and tablet properties using multivariate data analysis |